MGX supply chain intelligence for Metagenomi Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Metagenomi Therapeutics, Inc. (MGX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IONIS | IONIS | 92% | The Company will manufacture all licensed systems and certain components of the applicable licensed products that are needed by Ionis for use in its development activities and all of the Company’s ma… |
| CRBU | Caribou Biosciences, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: Reciprocal relationship from MGX graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from MGX graph: Reciprocal relationship from CRBU gra… |
| CRSP | CRISPR Therapeutics AG | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any t… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from MGX graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from MGX graph: amples of any lot of any approved pro… |
| DTIL | Precision BioSciences, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| EDIT | Editas Medicine, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any t… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: Reciprocal relationship from MGX graph: elopment, manufacture and commercialization of programs or product candidates. If these collaborations are not success… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | elopment, manufacture and commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected. As part of our strategy, we have e… |
| MYGN | Myriad Genetics, Inc. | 72% | ring passwords for our computers. Additionally, we execute confidentiality agreements with any third parties to whom we may provide access to the information and with our employees, consultants, scie… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from MGX graph: ring passwords for our computers. Additionally, we execute confidentiality agreements with any third parties to whom w… |
| NTLA | Intellia Therapeutics, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from MGX graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from MGX graph: Reciprocal relationship from NTLA gra… |
| QURE | uniQure N.V. | 72% | evenue and achieve or maintain profitability; • the level of taxes that we are required to pay; and • the availability of capital. Any reduction in reimbursement from Medicare or other government pro… |
| QURE | uniQure N.V. | 72% | Reciprocal relationship from QURE graph: Reciprocal relationship from MGX graph: evenue and achieve or maintain profitability; • the level of taxes that we are required to pay; and • the availability… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any t… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGX graph: Reciprocal relationship from SNYNF … |
| SNYNF | Sanofi | 72% | ring passwords for our computers. Additionally, we execute confidentiality agreements with any third parties to whom we may provide access to the information and with our employees, consultants, scie… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IONS | Ionis Pharmaceuticals, Inc. | 85% | Reciprocal relationship from IONS graph: Reciprocal relationship from MGX graph: elopment, manufacture and commercialization of programs or product candidates. If these collaborations are not success… |
| IONS | Ionis Pharmaceuticals, Inc. | 85% | elopment, manufacture and commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected. As part of our strategy, we have e… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Contents Third-party payors, whether domest… |
| CRBU | Caribou Biosciences, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| CRSP | CRISPR Therapeutics AG | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from MGX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from MGX graph: amples of any lot of any approved pro… |
| DTIL | Precision BioSciences, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any t… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any t… |
| EDIT | Editas Medicine, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any ti… |
| LLY | Eli Lilly and Company | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| NTLA | Intellia Therapeutics, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any t… |
| QURE | uniQure N.V. | 72% | evenue and achieve or maintain profitability; • the level of taxes that we are required to pay; and • the availability of capital. Any reduction in reimbursement from Medicare or other government pro… |
| QURE | uniQure N.V. | 72% | Reciprocal relationship from QURE graph: Reciprocal relationship from MGX graph: evenue and achieve or maintain profitability; • the level of taxes that we are required to pay; and • the availability… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from MGX graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from MGX graph: Reciprocal relationship from SGMO gra… |
| CAPITAL-RESOURCES | CAPITAL-RESOURCES | 62% | of our common stock from time to time and at our sole discretion, through Jefferies as our sales agent, by any method permitted that is deemed to be an “at the market offering” as defined in Rule 415… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MGX-DEBT | Debt stack $39.2M | 90% | Market cache reports total debt of $39.2M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MGX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 51 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| LGND | Ligand Pharmaceuticals Incorporated | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AKTS | Aktis Oncology, Inc. | 100.00 | 2 | |
| BDRX | Biodexa Pharmaceuticals Plc | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| VEEV | Veeva Systems Inc. | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 |